480423-17-4

Basic information

• Product Name: N-Tosyl-4-bromo-2-iodo-7-azaindole
• Synonyms: N-Tosyl-4-bromo-2-iodo-7-azaindole;4-Bromo-2-iodo-1-tosyl-1H-pyrrolo[2,3-b]pyridine;4-Bromo-2-iodo-N-tosyl-7-azaindole;1H-Pyrrolo[2,3-b]pyridine, 4-broMo-2-iodo-1-[(4-Methylphenyl)sulfonyl]-;4-bromo-2-iodo-1-tosyl-7-azaindole;4-Bromo-2-iodo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine
• CAS NO: 480423-17-4
• Molecular Formula: C₁₄H₁₀BrIN₂O₂S
• Molecular Weight: 477.115
• Mol File: 480423-17-4.mol

Chemical Properties

• Boiling Point: 574.6°C at 760 mmHg
• Flash Point: 301.3°C
• Appearance: /
• Density: 2g/cm³
• Vapor Pressure: 3.31E-13mmHg at 25°C
• Refractive Index: 1.743
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: N-Tosyl-4-bromo-2-iodo-7-azaindole(CAS DataBase Reference)
• NIST Chemistry Reference: N-Tosyl-4-bromo-2-iodo-7-azaindole(480423-17-4)
• EPA Substance Registry System: N-Tosyl-4-bromo-2-iodo-7-azaindole(480423-17-4)

Safety Data

• Hazardous Substances Data: 480423-17-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
N-Tosyl-4-bromo-2-iodo-7-azaindole is utilized as a key intermediate in the synthesis of pharmaceutical compounds due to its unique structure and biological activity. Its presence in the molecule allows for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
N-Tosyl-4-bromo-2-iodo-7-azaindole serves as a valuable building block in organic synthesis, enabling the creation of more complex chemical structures. The presence of bromine and iodine atoms facilitates various synthetic transformations, making it a versatile component in the synthesis of a wide range of organic compounds.
Used in Chemical Research:
N-Tosyl-4-bromo-2-iodo-7-azaindole is employed as a research tool in chemical studies, providing insights into the reactivity and properties of substituted azaindole derivatives. Its unique structure allows researchers to explore new reaction pathways and develop innovative synthetic strategies.

InChI:InChI=1/C14H10BrIN2O2S/c1-9-2-4-10(5-3-9)21(19,20)18-13(16)8-11-12(15)6-7-17-14(11)18/h2-8H,1H3

Upstream product

• 348640-07-3 4-bromo-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 98-59-9 p-toluenesulfonyl chloride 
• 348640-06-2 4-bromo-7-azaindole 

Downstream Products

• 1030610-61-7 [(4-{4-bromo-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-2-yl}phenyl)methyl]dimethylamine 
• 1021950-50-4 4-bromo-2-phenyl-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
• 1089669-37-3 1,1-dimethylethyl 5-[1-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-3,4-dihydro-1(2H)-pyridinecarboxylate 

Relevant articles and documents

Development of Potent PfCLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials

The protein kinase PfCLK3 plays a critical role in the regulation of malarial parasite RNA splicing and is essential for the survival of blood stage Plasmodium falciparum. We recently validated PfCLK3 as a drug target in malaria that offers prophylactic,

DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS

The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.

General methods for the synthesis and late-stage diversification of 2,4-substituted 7-azaindoles

As part of a medicinal chemistry program, we adapted known synthetic methods for the late-stage diversification of 2,4-substituted 7-azaindoles. The strengths and weaknesses of these strategies are discussed. In the course of this work, three optimized co

TETRACYCLIC CDK9 KINASE INHIBITORS

Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3A, R3B, and R4 are as described herein. The compounds may be used as agents in the treatment of diseases, including cancer. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (Ia).

PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS

Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa)

CDK9 KINASE INHIBITORS

Disclosed are compound of Formula (Ia), wherein R1A, R1, R2, R10, J, L, T, X, Y, and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia).

PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, B, R1, R2, R3, R4a, R5, and Z are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as aurora.

NOVEL COMPOUNDS

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.